DOI: http://dx.doi.org/10.17305/bjbms.2017.1823 | Full Text: [PDF]

Angiotensinogen (AGT) gene missense polymorphisms (rs699 and rs4762) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus

Jana Makuc, Maja Šeruga, Matej Završnik, Ines Cilenšek, Daniel Petrovič

Abstract


Gene polymorphisms associated with the renin–angiotensin–aldosterone system (RAAS) have been extensively studied in diabetic nephropathy (DN) patients, due to therapeutic potential of targeting the RAAS and slowing down the disease progression. The aim of our study was to examine the association between angiotensinogen (AGT) gene polymorphisms (rs699 and rs4762) and DN in Caucasians with type 2 diabetes mellitus (T2DM). A total of 651 unrelated Slovenian (Caucasian) T2DM patients were tested for AGT rs699 and rs4762 polymorphisms using a novel fluorescence-based kompetitive allele-specific polymerase chain reaction (KASPar) assay. A study group consisted of 276 T2DM patients with DN, while control group included 375 patients without DN but who have had T2DM for >10 years. For rs699 polymorphism, the frequencies of GG, GA and AA genotypes were 20.6%, 52.2% and 27.2%, respectively in T2DM patients and 23.4%, 48.1% and 28.5%, respectively in controls. The distributions of GG, GA and AA genotypes for rs4762 polymorphism were 73.9%, 23.2% and 2.9%, respectively in T2DM patients and 70.4%, 27.5% and 2.1%, respectively in controls. No significant differences in the allele frequencies were found between T2DM patients and controls for both polymorphisms. AGT rs699 and rs4762 missense polymorphisms are not associated with DN in our subset of Slovenian T2DM patients.


Keywords


Angiotensinogen; AGT; rs699; rs4762; diabetic nephropathy; T2DM; type 2 diabetes mellitus

Full Text:

[PDF]

References


Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 2005;28(1):164-76. https://doi.org/10.2337/diacare.28.1.164.

Yacoub R, Campbell KN. Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis 2015;8:29-40. DOI: 10.2147/IJNRD.S37893.

Gnudi L, Goldsmith D. Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. F1000 Rep 2010;2:18.

DOI: 10.3410/M2-18.

Shlipak M. Diabetic nephropathy. BMJ Clin Evid 2009;2009. pii:0606.

Carpena MP, Rados DV, Sortica DA, Souza BM, Reis AF, Canani LH, et al. Genetics of diabetic nephropathy. Arq Bras Endocrinol Metabol 2010;54(3):253-61. https://doi.org/10.1590/S0004-27302010000300002.

Kato M, Natarajan R. Diabetic nephropathy - Emerging epigenetic mechanisms. Nat Rev Nephrol 2014;10(9):517-30. https://doi.org/10.1038/nrneph.2014.116.

Van Buren PN, Toto R. Hypertension in diabetic nephropathy: Epidemiology, mechanisms, and management. Adv Chronic Kidney Dis 2011;18(1):28-41. https://doi.org/10.1053/j.ackd.2010.10.003.

Ahmad J. Management of diabetic nephropathy: Recent progress and future perspective. Diabetes Metab Syndr 2015;9(4):343-58. https://doi.org/10.1016/j.dsx.2015.02.008.

Rahimi Z, Moradi M, Nasri H. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. J Res Med Sci 2014;19(11):1090-8.

Kamiyama M, Urushihara M, Morikawa T, Konishi Y, Imanishi M, Nishiyama A, et al. Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy. Int J Mol Sci 2013;14(11):23045-62. https://doi.org/10.3390/ijms141123045.

Urushihara M, Kagami S. Urinary angiotensinogen as a biomarker of nephropathy in childhood. Int J Nephrol 2011;2011:206835. https://doi.org/10.4061/2011/206835.

Ewens KG, George RA, Sharma K, Ziyadeh FN, Spielman RS. Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes 2005;54(11):3305-18. https://doi.org/10.2337/diabetes.54.11.3305.

Rizvi S, Raza ST, Mahdi F. Association of genetic variants with diabetic nephropathy. World J Diabetes 2014;5(6):809-16. https://doi.org/10.4239/wjd.v5.i6.809.

Gao T, Huang L, Fu Q, Bai Y. Association of polymorphisms in the AGT gene (M235T, T174M) with ischemic stroke in the Chinese population. J Renin Angiotensin Aldosterone Syst 2015;16(3):681-6. https://doi.org/10.1177/1470320315583600.

Gaillard I, Clauser E, Corvol P. Structure of human angiotensinogen gene. DNA 1989;8(2):87-99. https://doi.org/10.1089/dna.1.1989.8.87.

Moon JY. Recent update of renin-angiotensin-aldosterone system in the pathogenesis of hypertension. Electrolyte Blood Press 2013;11(2):41-5. https://doi.org/10.5049/EBP.2013.11.2.41.

Brand E, Chatelain N, Paillard F, Tiret L, Visvikis S, Lathrop M, et al. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur J Hum Genet 2002;10(11):715-23. https://doi.org/10.1038/sj.ejhg.5200874.

Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis. Arterioscler Thromb Vasc Biol 2003;23(7):1269-75. https://doi.org/10.1161/01.ATV.0000079007.40884.5C.

World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consult. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance; 1999. p. 1-59.

Elston RC, Forthofer R. Testing for Hardy-Weinberg equilibrium in small samples. Biometrics 1977;33(3):536-42. https://doi.org/10.2307/2529370.

Norton GR, Brooksbank R, Woodiwiss AJ. Gene variants of the renin-angiotensin system and hypertension: From a trough of disillusionment to a welcome phase of enlightenment? Clin Sci (Lond) 2010;118(8):487-506. https://doi.org/10.1042/CS20090498.

Underwood PC, Sun B, Williams JS, Pojoga LH, Raby B, Lasky-Su J, et al. The association of the angiotensinogen gene with insulin sensitivity in humans: A tagging single nucleotide polymorphism and haplotype approach. Metabolism 2011;60(8):1150-7. https://doi.org/10.1016/j.metabol.2010.12.009.

Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A, Gupta R, et al. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet 2006;7:42. https://doi.org/10.1186/1471-2350-7-42.

Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Bhansali A, Sud K, et al. ACE variants interact with the RAS pathway to confer risk and protection against Type 2 diabetic nephropathy. DNA Cell Biol 2009;28(3):141-50. https://doi.org/10.1089/dna.2008.0810.

Shaikh R, Shahid SM, Mansoor Q, Ismail M, Azhar A. Genetic variants of ACE (insertion/deletion) and AGT (M268T) genes in patients with diabetes and nephropathy. J Renin Angiotensin Aldosterone Syst 2014;15(2):124-30. https://doi.org/10.1177/1470320313512390.

Mtiraoui N, Ezzidi I, Turki A, Chaieb M, Mahjoub T, Almawi WY. Renin-angiotensin-aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients. J Renin Angiotensin Aldosterone Syst 2011;12(4):572-80. https://doi.org/10.1177/1470320310396542.

Chang HR, Cheng CH, Shu KH, Chen CH, Lian JD, Wu MY. Study of the polymorphism of angiotensinogen, anigiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan. J Chin Med Assoc 2003;66(1):51-6.

Osawa N, Koya D, Araki S, Uzu T, Tsunoda T, Kashiwagi A, et al. Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Genet 2007;52(2):143-51.

https://doi.org/10.1007/s10038-006-0090-5.

Wang J, Zhu X, Yang L, Liu Y, Zhou W, Li H. Relationship between angiotensinogen gene M235T variant with diabetic nephropathy in Chinese NIDDM. Chin Med J (Engl) 1999;112(9):797-800.

Reis KA, Ebinç FA, Koç E, Demirci H, Erten Y, Güz G, et al. Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail 2011;33(5):469-74. https://doi.org/10.3109/0886022X.2011.568133.

Su SL, Yang HY, Wu CC, Lee HS, Lin YF, Hsu CA, et al. Gene-gene interactions in renin-angiotensin-aldosterone system contributes to end-stage renal disease susceptibility in a Han Chinese population. ScientificWorldJournal 2014;2014:169798. DOI: 10.1155/2014/169798.

Ding W, Wang F, Fang Q, Zhang M, Chen J, Gu Y. Association between two genetic polymorphisms of the renin-angiotensin-aldosterone system and diabetic nephropathy: A meta-analysis. Mol Biol Rep 2012;39(2):1293-303.

https://doi.org/10.1007/s11033-011-0862-7.

Buraczynska M, Ksiazek P, Lopatynski J, Spasiewicz D, Nowicka T, Ksiazek A. Association of the renin-angiotensin system gene polymorphism with nephropathy in type II diabetes. [Article in Polish]. Pol Arch Med Wewn 2002;108(2):725-30.

Ringel J, Beige J, Kunz R, Distler A, Sharma AM. Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension. Diabetologia 1997;40(2):193-9. https://doi.org/10.1007/s001250050662.

Campbell CY, Fang BF, Guo X, Peralta CA, Psaty BM, Rich SS, et al. Associations between genetic variants in the ACE, AGT, AGTR1 and AGTR2 genes and renal function in the Multi-ethnic Study of Atherosclerosis. Am J Nephrol 2010;32(2):156-62. https://doi.org/10.1159/000315866.


Refbacks

  • There are currently no refbacks.





Quick links for Authors:Quick links for Peer Reviewers:
Quick links for the Editor and Section Editors:Quick links for Editor and Publisher:

Advanced online | Current Issue | Archives | Submit a manuscript | About the Journal

© Association of Basic Medical Sciences of FBIH, 1998-2016. Credits to Public Knowledge Project